CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine

被引：0
|
作者：
Xinna Zhou
Guoliang Qiao
Xiaoli Wang
Qingkun Song
Michael A. Morse
Amy Hobeika
William R. Gwin
Jun Ren
H. Kim Lyerly
机构：
[1] Capital Medical University Cancer Center,Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines
[2] Beijing Shijitan Hospital,Department of Medical Oncology
[3] Capital Medical University,Department of Medicine
[4] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education),Department of Surgery
[5] Beijing Cancer Hospital and Institute,Department of Medicine
[6] Peking University School of Oncology,undefined
[7] Duke University Medical Center,undefined
[8] Duke University Medical Center,undefined
[9] University of Washington,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2018年 / 81卷
关键词：
CYP1A1; Single nucleotide polymorphism; Breast cancer; Liver metastasis; Docetaxel; Thiotepa; Capecitabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：365 / 372
页数：7
相关论文
共 50 条
  • [41] CYP2A6 genetic polymorphism as a predictive marker for clinical outcomes in patients (pts) with metastastic gastric carcinoma (MGC) treated with S-1 plus docetaxel
    Park, S. R.
    Park, M. S.
    Park, Y. L.
    Kim, N. K.
    Lee, J. S.
    Kim, H. K.
    Lim, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy
    Bayraktar, Soley
    Royce, Melanie
    Stork-Sloots, Lisette
    de Snoo, Femke
    Glueck, Stefan
    MEDICAL ONCOLOGY, 2014, 31 (10) : 1 - 7
  • [43] Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy
    Soley Bayraktar
    Melanie Royce
    Lisette Stork-Sloots
    Femke de Snoo
    Stefan Glück
    Medical Oncology, 2014, 31
  • [44] A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer
    Fury, Matthew G.
    Sherman, Eric
    Ho, Alan L.
    Xiao, Han
    Tsai, Frank
    Nwankwo, Oby
    Sima, Camelia
    Heguy, Adrian
    Katabi, Nora
    Haque, Sofia
    Pfister, David G.
    CANCER, 2013, 119 (10) : 1823 - 1831
  • [45] Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer
    Kong, Sun-Young
    Lim, Hyeong-Seok
    Nam, Byung-Ho
    Kook, Myeong-Cherl
    Kim, Young-Woo
    Ryu, Keun Won
    Lee, Jun Ho
    Choi, Il Ju
    Lee, Jin Soo
    Park, Young-lee
    Kim, Noe Kyeong
    Park, Sook Ryun
    PHARMACOGENOMICS, 2009, 10 (07) : 1147 - 1155
  • [46] A Phase III, Randomized, Double-Blind, Placebo-Controlled Registration Trial To Evaluate the Efficacy and Safety of Pertuzumab plus Trastuzumab plus Docetaxel vs. Placebo plus Trastuzumab plus Docetaxel in Patients with Previously Untreated HER2-Positive Metastatic Breast Cancer (CLEOPATRA)
    Baselga, J.
    Kim, S-B
    Im, S-A
    Hegg, R.
    im, Y-H
    Roman, L.
    Pedrini, J. L.
    Cortes, J.
    Knott, A.
    Clark, E.
    Ross, G. A.
    Swain, S. M.
    CANCER RESEARCH, 2011, 71
  • [47] Evaluation on efficacy and safety of capecitabine plus docetaxel versus docetaxel monotherapy in metastatic breast cancer patients pretreated with anthracycline: Results from a randomized phase Ill study (J021095)
    Sato, N.
    Yamamoto, D.
    Rai, Y.
    Iwase, H.
    Saito, M.
    Iwata, H.
    Masuda, N.
    Oura, S.
    Watanabe, J.
    Kuroi, K.
    CANCER RESEARCH, 2012, 72
  • [48] Single Nucleotide Polymorphism (SNP) in RASSF1 and Clinical Outcomes of Breast Cancer Patients Treated with Neoadjuvant Docetaxel/Doxorubicin Chemotherapy
    Keam, B.
    Kim, H-J
    Im, S-A
    Han, S-W
    Oh, D-Y
    Kim, J. H.
    Lee, S-H
    Chie, E. K.
    Han, W.
    Kim, D-W
    Cho, N.
    Moon, W. K.
    Kim, T-Y
    Park, I. A.
    Noh, D-Y
    Heo, D. S.
    Ha, S. W.
    Bang, Y-J
    CANCER RESEARCH, 2009, 69 (24) : 843S - 843S
  • [49] Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel
    Kus, Tulay
    Aktas, Gokmen
    Kalender, Mehmet Emin
    Demiryurek, Abdullah Tuncay
    Ulasli, Mustafa
    Oztuzcu, Serdar
    Sevinc, Alper
    Kul, Seval
    Camci, Celaletdin
    ONCOTARGETS AND THERAPY, 2016, 9 : 5073 - 5080
  • [50] S-1 plus oxaliplatin versus capecitabine plus oxaliplatin chemotherapy in the treatment of patients with metastatic colorectal cancer: A meta-analysis
    Lalusis, J.
    Pandy, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S94 - S94
12345